FDA tells Roche that AmpliChip will need premarket review
This article was originally published in Clinica
Executive Summary
The US FDA has decided that the first major product to enter the futuristic world of personalised medicine, where drugs are prescribed based on a person's genetic profile, must undergo a lengthy review process before it can be commercialised.